Trial Profile
A phase II trial of combination therapy with celecoxib and Taxotere [docetaxel] for the treatment of stage D3 prostate cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Celecoxib (Primary) ; Docetaxel (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 27 Nov 2005 New trial record.